Novocure Ltd. Plans Regulatory Filing for TTFields Therapy in Pancreatic Cancer in U.S. by 2025

Reuters

05-31

Novocure Ltd. Plans Regulatory Filing for TTFields Therapy in Pancreatic Cancer in U.S. by 2025

Novocure Ltd. has announced plans to file for regulatory approval for its Tumor Treating Fields (TTFields) therapy for unresectable, locally advanced pancreatic adenocarcinoma based on the results of the Phase 3 PANOVA-3 trial. The filings are expected to occur in the second half of 2025 in the United States, with subsequent submissions planned for the European Union, Japan, and other key markets. The PANOVA-3 trial demonstrated that TTFields therapy, when used in conjunction with gemcitabine and nab-paclitaxel, provided a significant improvement in overall survival for patients. The results were presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting and published in the Journal of Clinical Oncology.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novocure Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250531920957) on May 31, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2539978618"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2539978618\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2539978618?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-31 20:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2539978618","market":"us","top_or_hot":-1,"title":"Novocure Ltd. Plans Regulatory Filing for TTFields Therapy in Pancreatic Cancer in U.S. by 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Novocure Ltd. Plans Regulatory Filing for TTFields Therapy in Pancreatic Cancer in U.S. by 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Novocure Ltd. has announced plans to file for regulatory approval for its Tumor Treating Fields (TTFields) therapy for unresectable, locally advanced pancreatic adenocarcinoma based on the results of the Phase 3 PANOVA-3 trial. The filings are expected to occur in the second half of 2025 in the United States, with subsequent submissions planned for the European Union, Japan, and other key markets. The PANOVA-3 trial demonstrated that TTFields therapy, when used in conjunction with gemcitabine and nab-paclitaxel, provided a significant improvement in overall survival for patients. The results were presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting and published in the Journal of Clinical Oncology.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novocure Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250531920957) on May 31, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novocure Ltd. Plans Regulatory Filing for TTFields Therapy in Pancreatic Cancer in U.S. by 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovocure Ltd. Plans Regulatory Filing for TTFields Therapy in Pancreatic Cancer in U.S. by 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-05-31 20:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Novocure Ltd. Plans Regulatory Filing for TTFields Therapy in Pancreatic Cancer in U.S. by 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Novocure Ltd. has announced plans to file for regulatory approval for its Tumor Treating Fields (TTFields) therapy for unresectable, locally advanced pancreatic adenocarcinoma based on the results of the Phase 3 PANOVA-3 trial. The filings are expected to occur in the second half of 2025 in the United States, with subsequent submissions planned for the European Union, Japan, and other key markets. The PANOVA-3 trial demonstrated that TTFields therapy, when used in conjunction with gemcitabine and nab-paclitaxel, provided a significant improvement in overall survival for patients. The results were presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting and published in the Journal of Clinical Oncology.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novocure Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250531920957) on May 31, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250531:nNDLvRf40:1","article_id":"2539978618","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2539978618","pubTimestamp":1748692864,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Novocure Ltd. has announced plans to file for regulatory approval for its Tumor Treating Fields  therapy for unresectable, locally advanced pancreatic adenocarcinoma based on the results of the Phase 3 PANOVA-3 trial. The filings are expected to occur in the second half of 2025 in the United States, with subsequent submissions planned for the European Union, Japan, and other key markets. The PANOVA-3 trial demonstrated that TTFields therapy, when used in conjunction with gemcitabine and nab-paclitaxel, provided a significant improvement in overall survival for patients. The results were presented at the 2025 American Society of Clinical Oncology  Annual Meeting and published in the Journal of Clinical Oncology.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, invest","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","BK4588":"碎股","BK4548":"巴美列捷福持仓","NVCR":"NovoCure Limited","BK4082":"医疗保健设备","BK4534":"瑞士信贷持仓"},"translate_title":"Novocure Ltd.计划到2025年在美国向监管机构提交TTFields治疗胰腺癌的申请","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVCR":0.9},"content_text":"Novocure Ltd. Plans Regulatory Filing for TTFields Therapy in Pancreatic Cancer in U.S. by 2025\n    \n\n        Novocure Ltd. has announced plans to file for regulatory approval for its Tumor Treating Fields (TTFields) therapy for unresectable, locally advanced pancreatic adenocarcinoma based on the results of the Phase 3 PANOVA-3 trial. The filings are expected to occur in the second half of 2025 in the United States, with subsequent submissions planned for the European Union, Japan, and other key markets. The PANOVA-3 trial demonstrated that TTFields therapy, when used in conjunction with gemcitabine and nab-paclitaxel, provided a significant improvement in overall survival for patients. The results were presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting and published in the Journal of Clinical Oncology.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novocure Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250531920957) on May 31, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}